Postinfarct cardiac remodeling and the substrate for sudden cardiac death: role of oxidative stress and myocardial fibrosis

References

• Cao JM, Fishbein MC, Han JB et al. Relationship between regional cardiac hyperinnervation and ventricular arrhythmia. Circulation101(16), 1960–1969 (2000).
   PubMed Web of Science ®Google Scholar
• Wilson LD, Rosenbaum DS. Mechanisms of arrythmogenic cardiac alternans. Europace9(Suppl. 6), vi77–vi82 (2007).
   PubMed Web of Science ®Google Scholar
• Santana LF, Nunez-Duran H, Dilly KW, Lederer WJ. Sodium current and arrhythmogenesis in heart failure. Heart Fail. Clin.1(2), 193–205 (2005).
   PubMedGoogle Scholar
• Frantz S, Bauersachs J, Ertl G. Post-infarct remodelling: contribution of wound healing and inflammation. Cardiovasc. Res.81(3), 474–481 (2009).
   PubMed Web of Science ®Google Scholar
• Seddon M, Looi YH, Shah AM. Oxidative stress and redox signalling in cardiac hypertrophy and heart failure. Heart93(8), 903–907 (2007).
   PubMed Web of Science ®Google Scholar
• Fukui T, Yoshiyama M, Hanatani A, Omura T, Yoshikawa J, Abe Y. Expression of p22-phox and gp91-phox, essential components of NADPH oxidase, increases after myocardial infarction. Biochem. Biophys. Res. Commun.281(5), 1200–1206 (2001).
   PubMed Web of Science ®Google Scholar
• Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc. Res.81(3), 482–490 (2009).
   PubMed Web of Science ®Google Scholar
• Hill MF, Singal PK. Right and left myocardial antioxidant responses during heart failure subsequent to myocardial infarction. Circulation96(7), 2414–2420 (1997).
   PubMed Web of Science ®Google Scholar
• Kabe Y, Ando K, Hirao S, Yoshida M, Handa H. Redox regulation of NF-κB activation: distinct redox regulation between the cytoplasm and the nucleus. Antioxid. Redox Signal.7(3–4), 395–403 (2005).
   PubMed Web of Science ®Google Scholar
• Schoonbroodt S, Piette J. Oxidative stress interference with the nuclear factor-kappa B activation pathways. Biochem. Pharmacol.60(8), 1075–1083 (2000).
   PubMed Web of Science ®Google Scholar
• Hill MF, Singal PK. Antioxidant and oxidative stress changes during heart failure subsequent to myocardial infarction in rats. Am. J. Pathol.148(1), 291–300 (1996).
   PubMed Web of Science ®Google Scholar
• Kinugawa S, Tsutsui H, Hayashidani S et al. Treatment with dimethylthiourea prevents left ventricular remodeling and failure after experimental myocardial infarction in mice: role of oxidative stress. Circ. Res.87(5), 392–398 (2000).
   PubMed Web of Science ®Google Scholar
• Singh RB, Niaz MA, Rastogi SS, Rastogi S. Usefulness of antioxidant vitamins in suspected acute myocardial infarction (the Indian experiment of infarct survival-3). Am. J. Cardiol.77(4), 232–236 (1996).
   PubMed Web of Science ®Google Scholar
• Kim KS, Takeda K, Sethi R et al. Protection from reoxygenation injury by inhibition of rac-1. J. Clin. Invest.101(9), 1821–1826 (1998).
   PubMed Web of Science ®Google Scholar
• Di LF, Canton M, Carpi A et al. Mitochondrial injury and protection in ischemic pre- and post-conditioning. Antioxid. Redox Signal.14(5), 881–891 (2011).
   PubMed Web of Science ®Google Scholar
• Canton M, Menazza S, Sheeran FL, Polverino de Laureto P, Di LF, Pepe S. Oxidation of myofibrillar proteins in human heart failure. J. Am. Coll. Cardiol.57(3), 300–309 (2011).
   PubMed Web of Science ®Google Scholar
• Grieve DJ, Byrne JA, Cave AC, Shah AM. Role of oxidative stress in cardiac remodelling after myocardial infarction. Heart Lung Circ.13(2), 132–138 (2004).
   PubMedGoogle Scholar
• Beresewicz A, Horackova M. Alterations in electrical and contractile behavior of isolated cardiomyocytes by hydrogen peroxide: possible ionic mechanisms. J. Mol. Cell Cardiol.23(8), 899–918 (1991).
   PubMed Web of Science ®Google Scholar
• Morita N, Sovari AA, Xie Y et al. Increased susceptibility of aged hearts to ventricular fibrillation during oxidative stress. Am. J. Physiol. Heart Circ. Physiol.297(5), H1594–H1605 (2009).
   PubMed Web of Science ®Google Scholar
• Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L. Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction. J. Pharmacol. Exp. Ther.318(1), 214–222 (2006).
   PubMed Web of Science ®Google Scholar
• Morita N, Lee JH, Xie Y et al. Suppression of re-entrant and multifocal ventricular fibrillation by the late sodium current blocker ranolazine. J. Am. Coll. Cardiol.57(3), 366–375 (2011).
   PubMed Web of Science ®Google Scholar
• Thomas GP, Sims SM, Cook MA, Karmazyn M. Hydrogen peroxide-induced stimulation of L-type calcium current in guinea pig ventricular myocytes and its inhibition by adenosine A1 receptor activation. J. Pharmacol. Exp. Ther.286(3), 1208–1214 (1998).
   PubMed Web of Science ®Google Scholar
• Anzai K, Ogawa K, Kuniyasu A, Ozawa T, Yamamoto H, Nakayama H. Effects of hydroxyl radical and sulfhydryl reagents on the open probability of the purified cardiac ryanodine receptor channel incorporated into planar lipid bilayers. Biochem. Biophys. Res. Commun.249(3), 938–942 (1998).
   PubMed Web of Science ®Google Scholar
• Murrell GA, Francis MJ, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. Biochem. J.265(3), 659–665 (1990).
   PubMed Web of Science ®Google Scholar
• Cu A, Ye Q, Sarria R, Nakamura S, Guzman J, Costabel U. N-acetylcysteine inhibits TNF-alpha, sTNFR, and TGF-beta-1 release by alveolar macrophages in idiopathic pulmonary fibrosis in vitro. Sarcoidosis Vasc. Diffuse Lung Dis.26(2), 147–154 (2009).
   PubMed Web of Science ®Google Scholar
• Koli K, Myllarniemi M, Keski-Oja J, Kinnula VL. Transforming growth factor-beta activation in the lung: focus on fibrosis and reactive oxygen species. Antioxid. Redox Signal.10(2), 333–342 (2008).
   PubMed Web of Science ®Google Scholar
• Sesso HD, Buring JE, Christen WG et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians’ Health Study II randomized controlled trial. J. Am. Med. Assoc.300(18), 2123–2133 (2008).
   PubMed Web of Science ®Google Scholar
• Sovari AA, Morita N, Karagueuzian HS. Apocynin: a potent NADPH oxidase inhibitor for the management of atrial fibrillation. Redox Rep.13(6), 242–245 (2008).
   PubMed Web of Science ®Google Scholar
• Sovari AA, Iravanian S, Mitchell D et al. Mitochondria-targeted antioxidant, Mito-TEMPO, prevents angiotensin II mediated connexin 43 remodeling and sudden cardiac death. J. Investig. Med.59(4), 692–730 (2011).
   Google Scholar
• Sacher F, Tedrow UB, Field ME et al. Ventricular tachycardia ablation: evolution of patients and procedures over 8 years. Circ. Arrhythm. Electrophysiol.1(3), 153–161 (2008).
   PubMed Web of Science ®Google Scholar
• Cleutjens JP, Verluyten MJ, Smiths JF, Daemen MJ. Collagen remodeling after myocardial infarction in the rat heart. Am. J. Pathol.147(2), 325–338 (1995).
   PubMed Web of Science ®Google Scholar
• van Kats JP, Duncker DJ, Haitsma DB et al. Angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade prevent cardiac remodeling in pigs after myocardial infarction: role of tissue angiotensin II. Circulation102(13), 1556–1563 (2000).
   PubMed Web of Science ®Google Scholar
• Funabiki K, Onishi K, Dohi K et al. Combined angiotensin receptor blocker and ACE inhibitor on myocardial fibrosis and left ventricular stiffness in dogs with heart failure. Am. J. Physiol. Heart Circ. Physiol.287(6), H2487–H2492 (2004).
   Google Scholar
• Onishi K, Dohi K, Koji T et al. Candesartan prevents myocardial fibrosis during progression of congestive heart failure. J. Cardiovasc. Pharmacol.43(6), 860–867 (2004).
   PubMed Web of Science ®Google Scholar
• Sovari AA, Morita N, Weiss JN, Karagueuzian HS. Serum transforming growth factor-beta-1 as a risk stratifier of sudden cardiac death. Med. Hypotheses71(2), 262–265 (2008).
   PubMed Web of Science ®Google Scholar
• Noble PW, Albera C, Bradford WZ et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet377(9779), 1760–1769 (2011).
   PubMed Web of Science ®Google Scholar
• Sharma K, Ix JH, Mathew AV et al. Pirfenidone for diabetic nephropathy. J. Am. Soc. Nephrol.22(6), 1144–1151 (2011).
   PubMed Web of Science ®Google Scholar
• Armendariz-Borunda J, Lyra-Gonzalez I, Medina-Preciado D et al. A controlled clinical trial with pirfenidone in the treatment of pathological skin scarring caused by burns in pediatric patients. Ann. Plast. Surg.68(1), 22–28 (2011).
   Web of Science ®Google Scholar
• Assomull RG, Prasad SK, Lyne J et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J. Am. Coll. Cardiol.48(10), 1977–1985 (2006).
   PubMed Web of Science ®Google Scholar